In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Updated March 30th, 2022

In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Already approved for EGFR-positive metastatic non-small cell lung cancer, osimertinib (Tagrisso ) brings major benefits in early cancer, too.

NOW
PLAYING
Incredible New Results For New Brain Cancer Treatment-- Disease That Took John McCain-- Complete Tumor Regression
NOW
PLAYING
For Advanced Lung Cancer With the EGFR Mutation, the Drug Tagrisso & Chemotherapy Extends Life
NOW
PLAYING
Elahere: A Drug for Hard-To-Treat Ovarian Cancer
NOW
PLAYING
One-Legged Man, 23, Diagnosed With Stage 4 Lung Cancer Runs Marathon on Crutches While Celebrating 5 Years in Remission, Credits Clinical Trials
NOW
PLAYING
Next-Generation Sequencing (NGS) Helps Identify Exact Mutations in Lung Cancer
NOW
PLAYING
Molecular Testing for Lung Cancer

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... lung cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.